Dihydroergotamine and sumatriptan in isolated human coronary artery, middle meningeal artery and saphenous vein

Sieneke Labruijere, Kayi Y. Chan, René de Vries, Antoon Bogaerdt, Clemens Dirven, Jan Danser, Shashidhar H. Kori, Antoinette Maassen van den Brink*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

16 Citations (Scopus)

Abstract

Background Dihydroergotamine (DHE) and sumatriptan are contraindicated in patients with cardiovascular disease because of their vasoconstricting properties, which have originally been explored in proximal coronary arteries. Our aim was to investigate DHE and sumatriptan in the proximal and distal coronary artery, middle meningeal artery and saphenous vein. Methods Blood vessel segments were mounted in organ baths and concentration response curves for DHE and sumatriptan were constructed. Results In the proximal coronary artery, meningeal artery and saphenous vein, maximal contractions to DHE (proximal: 8±4%; meningeal: 32±7%; saphenous: 52±11%) and sumatriptan (proximal: 17±7%; meningeal: 61±18%, saphenous: 37±8%) were not significantly different. In the distal coronary artery, contractions to DHE (5±2%) were significantly smaller than those to sumatriptan (17±9%). At clinically relevant concentrations, mean contractions to DHE and sumatriptan were below 3% in proximal coronary arteries and below 6% in distal coronary arteries. Contractions in the meningeal artery and saphenous vein were higher (7%-38%). Conclusions Contractions to DHE in distal coronary arteries are smaller than those to sumatriptan, while at clinical concentrations they both induce only slight contractions. In meningeal arteries contractions to DHE and sumatriptan are significantly larger, showing their cranioselectivity. Contractions to DHE in the saphenous vein are higher than those in the arteries, confirming its venous contractile properties.
Original languageEnglish
Pages (from-to)182-189
Number of pages8
JournalCephalalgia
Volume35
Issue number2
Early online date30 Jul 2014
DOIs
Publication statusPublished - 2015

Bibliographical note

This study was supported by the Netherlands Organization
for Scientific Research (Vidi grant 917.11.349) and by MAP
Pharmaceuticals/Allergan

Research programs

  • EMC COEUR-09
  • EMC COEUR-09-39-02

Fingerprint

Dive into the research topics of 'Dihydroergotamine and sumatriptan in isolated human coronary artery, middle meningeal artery and saphenous vein'. Together they form a unique fingerprint.

Cite this